]>The Potential for Xanthine Oxidase Inhibition in the Prevention and Treatment of Cardiovascular and Cerebrovascular Disease : Table 1
Table 1: The relationship between serum uric acid and vascular outcomes.
RefPopulationChange in outcome measure
[5]Acute strokeRR 1.27 (1.18–1.36 ) a for recurrent vascular events
[6]Acute strokeSerum uric acid ↑ in those with early clinical deterioration ( 𝑃 = . 0 0 1 )
[7]Acute StrokeOR 1.37 (1.13–1.67) for early d e a t h b
[8]Acute StrokeOR 1.12 (1–1.25) per additional mg/dL uric acid for good outcome
[7]Acute StrokeOR 1.57 (1.02–2.42) for poor o u t c o m e ∗
[9]DiabetesHR 1.91 (1.24–2.94) for s t r o k e b
[10]Diabetes and strokeHR 1.49 (1.21–1.84) for recurrent CV e v e n t a
[11]Coronary DiseaseHR 1.5 (1.02–2.1) for all cause m o r t a l i t y b
[12]Coronary DiseaseHR 1.23 (1.11–1.36) for all cause m o r t a l i t y c
[13]HypertensionHR 1.32 (1.03–1.69), for CV e v e n t s b
[14]HypertensionHR 1.22 (1.11–1.35) for CV d i s e a s e d
[15]HypertensionHR 1.14 (1.02–1.27) for CV m o r t a l i t y e HR 1.34 (1.14–1.57) for fatal s t r o k e e
[16]HypertensionHR 1.73 (1.01–3) for CV event r a t e s b
[17]HypertensionHR 1.03 (0.93–1.14) for CV m o r t a l i t y e HR 1.06 (0.99–1.13) for all CV e v e n t s e
[18]Healthy VolunteersHR 1.16 ( 𝑃 < . 0 0 1 ) for all-cause m o r t a l i t y b HR 1.35 ( 𝑃 = . 0 2 ) for ischaemic s t r o k e b
[19]Healthy VolunteersHR 1.35 (1.20–1.52) for CV m o r t a l i t y b HR 1.37 (1.09–1.74) for s t r o k e b
[20]Healthy VolunteersOR 2.6 (1.2–5.4) for white matter hyperintense signals on MRI i m a g i n g b
Results expressed as ratio and 95% CI. a per additional 0.1 mmol/L in serum uric acid, b for highest versus lowest group, c , d per additional 0.6 and 0.86 mmol/L in serum uric acid respectively, e for each 50  𝜇 mol/L increment in serum uric acid. ∗ on univaiate analysis. RR—Relative risk, OR—Odds ratio, HR—Hazard ratio, CV—Cardiovascular.